💊 Naloxone (Buprenorphine And Naloxone)
Sublingual tablets indicated for the maintenance treatment of opioid dependence, used as part of a complete treatment plan that includes counseling and psychosocial support. They contain buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist.
In Arabic: بوبرينورفين ونالوكسون🏷️ Brand names & manufacturers
Naloxone Hydrochloride🏭 Amneal Pharmaceuticals NY LLCDailyMed✅ What it is used for
- Maintenance treatment of opioid dependence
- Use as part of a complete treatment plan that includes counseling and psychosocial support
🧪 Active ingredient
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
🌿 Benefits
- Maintenance treatment of opioid dependence as part of a complete treatment plan
- Sublingual buprenorphine produces typical opioid agonist effects which are limited by a ceiling effect as described in pharmacodynamic studies
📝 How to use
- Administer sublingually as a single daily dose
- Use in patients who have been initially inducted using buprenorphine sublingual tablets
- Doses are progressively adjusted to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms
- When discontinuing, gradually taper to avoid withdrawal signs and symptoms
💊 Dosage forms
- Sublingual tablet: buprenorphine 2 mg/naloxone 0.5 mg
- Sublingual tablet: buprenorphine 8 mg/naloxone 2 mg
⚠️ Common side effects
- Oral hypoesthesia
- Glossodynia
- Oral mucosal erythema
- Headache
- Nausea
- Vomiting
- Hyperhidrosis
- Constipation
- Signs and symptoms of withdrawal
- Insomnia
- Pain
- Peripheral edema
🚨 Serious — seek medical help
- Addiction, abuse, and misuse
- Respiratory and CNS depression
- Neonatal opioid withdrawal syndrome
- Adrenal insufficiency
- Opioid withdrawal
- Hepatitis, hepatic events
- Hypersensitivity reactions
- Orthostatic hypotension
- Elevation of cerebrospinal fluid pressure
- Elevation of intracholedochal pressure
⛔ Do not use if
- History of hypersensitivity to buprenorphine or naloxone (serious adverse reactions, including anaphylactic shock, have been reported)
❗ Warnings & precautions
- Buprenorphine can be abused in a similar manner to other opioids; clinical monitoring appropriate to the patient's level of stability is essential
- Life-threatening respiratory depression and death have occurred in association with buprenorphine use
- Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants
- Unintentional pediatric exposure: store safely out of the sight and reach of children; buprenorphine can cause severe, possibly fatal, respiratory depression in children
- Neonatal opioid withdrawal syndrome is an expected and treatable outcome of prolonged use of opioids during pregnancy
- Adrenal insufficiency: if diagnosed, treat with physiologic replacement of corticosteroids and wean the patient off the opioid
- Risk of opioid withdrawal with abrupt discontinuation: monitor patients for withdrawal and treat appropriately
- Monitor liver function tests prior to initiation and during treatment and evaluate suspected hepatic events
- Precipitation of opioid withdrawal signs and symptoms is likely with parenteral misuse or sublingual administration before the agonist effects of other opioids have subsided
- Not appropriate as an analgesic; deaths have been reported in opioid-naïve individuals who received a 2 mg sublingual dose
🔄 Drug interactions
- Benzodiazepines and other CNS depressants, including alcohol: additive pharmacologic effects can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death
- CYP3A4 inhibitors: can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects
🤰 Pregnancy
The data on use of buprenorphine in pregnancy are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. The extremely limited data on sublingual naloxone exposure in pregnancy are not sufficient to evaluate a drug-associated risk. Based on animal data, advise pregnant women of the potential risk to a fetus.
🍼 Breastfeeding
Buprenorphine passes into mother's milk.
🧒 Children
The safety and effectiveness of buprenorphine and naloxone sublingual tablets have not been established in pediatric patients. This product is not appropriate for the treatment of neonatal abstinence syndrome in neonates because it contains naloxone, an opioid antagonist.
👴 Older adults
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Due to possible decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy, the decision to prescribe should be made cautiously in individuals 65 years of age or older, and these patients should be monitored for signs and symptoms of toxicity or overdose.
🌡️ Storage
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Store securely and dispose of properly. Store safely out of the sight and reach of children.
🆘 Overdose
Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, hypoglycemia, respiratory depression, and death. Toxic leukoencephalopathy has been reported after opioid overdose and can present hours, days, or weeks after apparent recovery from the initial intoxication. In the event of overdose, monitor respiratory and cardiac status carefully; when respiratory or cardiac functions are depressed, give primary attention to re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation; oxygen, IV fluids, vasopressors, and other supportive measures should be employed as indicated. An opioid overdose reversal agent may be of value; higher than normal doses and repeated administration may be necessary due to the long duration of action.
💰 Price & brands in your area
Local prices are currently available for Palestine; more countries are coming. Ask your pharmacist for local price and alternatives.
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Labeled dosing
The maintenance dose is generally in the range of 4 mg/1 mg to 24 mg/6 mg per day and should be based on clinical response. Administer sublingually as a single daily dose. Induction with buprenorphine sublingual tablets should be undertaken when objective and clear signs of withdrawal are evident to avoid precipitating withdrawal. When discontinuing, gradually taper.
- Strongly consider recommending or prescribing an opioid overdose reversal agent (e.g., naloxone, nalmefene) when treatment is initiated or renewed
- Prescribe in consideration of the frequency of visits; provision of multiple refills is not advised early in treatment or without appropriate patient follow-up visits
- Use in patients who have been initially inducted using buprenorphine sublingual tablets
- Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors
🎓 Key points for students
- Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor
- Naloxone is an opioid antagonist and produces withdrawal when administered parenterally to individuals physically dependent on full opioid agonists
- Available strengths: 2 mg/0.5 mg and 8 mg/2 mg (4:1 ratio of free bases)
- Maintenance dose is generally 4 mg/1 mg to 24 mg/6 mg per day based on clinical response
- A ceiling effect was observed with sublingual buprenorphine in pharmacodynamic studies
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What are buprenorphine and naloxone sublingual tablets used for?
They are indicated for the maintenance treatment of opioid dependence as part of a complete treatment plan that includes counseling and psychosocial support.
How are these tablets taken?
They are administered sublingually as a single daily dose, and should be used in patients who have been initially inducted using buprenorphine sublingual tablets. Doses are progressively adjusted based on clinical response.
Can these tablets cause withdrawal?
Yes, opioid withdrawal signs and symptoms are likely with parenteral misuse or sublingual administration before the agonist effects of other opioids have subsided, and with abrupt discontinuation. Gradually taper when discontinuing treatment.
What are the key safety warnings?
Addiction, abuse, and misuse; life-threatening respiratory depression; risk with concomitant benzodiazepines or other CNS depressants; and unintentional pediatric exposure. Strongly consider recommending or prescribing an opioid overdose reversal agent.
Are they used in children?
The safety and effectiveness have not been established in pediatric patients, and the product is not appropriate for the treatment of neonatal abstinence syndrome because it contains naloxone.
How should they be stored?
Store at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F), securely and out of the sight and reach of children, and dispose of properly.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2026-01), simplified. Updated: 2026-11-16.